Features | Partner Sites | Information | LinkXpress
Sign In

Blood Test Detects Patients at Risk for Diabetes

By Christina Chang, LabMedica Regional Director
Posted on 17 Jul 2012
AACC 2012: A new test being showcased can stratify patients based on risk for developing diabetes.

Even within the healthy range of hemoglobin A1C, the test, dubbed Quantose, detects patients' risk of developing diabetes. It is a novel blood test for prediabetes that reflects insulin resistance. The test is based on three recently identified nonglycemic biomarkers and insulin, and detects progression to prediabetes earlier than traditional glycemic measures such a hemoglobin A1C.

Metabolon (Research Triangle Park, NC, USA) is showcasing the Quantose test, which is a metablomics-driven diagnostic, at the American Association for Clinical Chemistry Lab Expo (AACC) being held from July 15-19, 2012, in Los Angeles (CA, USA). Two posters highlighting the clinical utility of Quantose are being presented at the Expo.

In a poster, the clinical utility of Quantose as a simple, practical measure of insulin resistance will be demonstrated in this poster session with data highlighting the correlations between Quantose and other known risk factors for type 2 diabetes and cardiovascular disease.

In a second poster, differences in insulin resistance using HbA1c and metabolic markers Alpha-hydroxybutyrate, Linoleoyl-GPC, and Oleate are described. This clinical study was performed at the University of North Carolina (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance. Data include the finding that Quantose scores closely track worsening dysglycemia as defined by hemoglobin A1C, but that Quantose also identifies a substantial subset of patients as insulin resistant despite hemoglobin A1C values within the normal range (<5.7%). The clinical study was performed at the University of North Carolina, (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance.

Metabolon, Inc. has developed technology to quickly identify and measure all biochemicals in a biological sample. This method provides a precise understanding of disease etiology and drug action, and advances personalized medicine.

Related Links:

Metabolon
University of North Carolina




DiagCor Bioscience
KARL HECHT GMBH &amp; CO KG
CELLAVISION AB
comments powered by Disqus
Sekisui Diagnostics

Channels

Industry News

view channel

Roche Acquires High-Precision Dissection Technology from AvanSci Bio

Roche Diagnostics of the Roche group (Basel, Switzerland) has signed a definitive Asset Purchase Agreement with AvanSci Bio (Salt Lake City, UT, USA) for all products associated with the high-performance microdissection of slide-mounted tissue sections for subsequent molecular analysis. The system consists of instrumentation,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.